Improving early clinical trial phase identification of promising therapeutics

Neurology

Volumn 85, Issue 3, 2015, Pages 274-283

  Kent, Thomas A ^a,b,c   Shah, Shreyansh D ^a,b,c   Mandava, Pitchaiah ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Center for Translational Research in Inflammatory Diseases   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; BARTHEL INDEX; CLINICAL TRIAL (TOPIC); DECISION MAKING; GLASGOW OUTCOME SCALE; HISTORY; HUMAN; NATIONAL HEALTH ORGANIZATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; STROKE; TIME;

CLINICAL TRIALS AS TOPIC; HUMANS; STROKE; TIME FACTORS;

EID: 84937722381     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001757     Document Type: Review

References (60)

1. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467-477
2. Minnerup J, Wersching H, Schilling M, Schabitz WR. Analysis of early phase and subsequent phase III stroke studies of neuroprotectants: outcomes and predictors for success. Exp Transl Stroke Med 2014; 6: 2
3. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-To-moderate Alzheimer's disease. N Engl J Med 2014; 370: 322-333
4. Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, doubleblind, phase 3 trial. Lancet Neurol 2013; 12: 1059-1067
5. Robertson CS, Hannay HJ, Yamal JM, et al. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA 2014; 312: 36-47
6. Anderson CS, Heeley E, Huang Y, et al. Rapid bloodpressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355-2365
7. Chamorro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICOICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol 2014; 13: 453-460
8. Davalos A, Alvarez-Sabin J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012; 380: 349-357
9. Ringelstein EB, Thijs V, Norrving B, et al. Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke 2013; 44: 2681-2687
10. Ginsberg MD, Palesch YY, Hill MD, et al. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol 2013; 12: 1049-1058
11. The ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 2015; 385: 617-628
12. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013; 368: 893-903
13. Adams HP Jr, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53: 126-131
14. Mandava P, Kent TA. Intra-Arterial therapies for acute ischemic stroke. Neurology 2007; 68: 2132-2139
15. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006; 354: 588-600
16. Zivin JA, Albers GW, Bornstein N, et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke 2009; 40: 1359-1364
17. Crager MR. Analysis of covariance in parallel-group clinical trials with pretreatment baselines. Biometrics 1987; 43: 895-901
18. Hair JF, Black WC, Babin BJ, Anderson RE, Tatham RL. Multivariate analysis of variance. In: Multivariate Data Analysis, Chapter 6. Upper Saddle River, NJ: Pearson/Prentice-Hall; 2006: 383-458
19. Rosner B. Design and analysis techniques for epidemiologic studies. In: Fundamentals of Biostatistics. Boston, MA: Brooks/Cole; 2011: 588-724
20. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
21. Mandava P, Kalkonde YV, Rochat RH, Kent TA A matching algorithm to address imbalances in study populations: application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator acute stroke trial. Stroke 2010; 41: 765-770
22. Ingall TJ, O'Fallon WM, Asplund K, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004; 35: 2418-2424
23. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001; 57: 1595-1602
24. Ginsberg MD, Palesch YY, Martin RH, et al. The Albumin in Acute Stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. Stroke 2011; 42: 119-127
25. Uchino K, Billheimer D, Cramer SC. Entry criteria and baseline characteristics predict outcome in acute stroke trials. Stroke 2001; 32: 909-916
26. Mandava P, Kent TA A method to determine stroke trial success using multidimensional pooled control functions. Stroke 2009; 40: 1803-1810
27. Ntaios G, Egli M, Faouzi M, Michel P. J-shaped association between serum glucose and functional outcome in acute ischemic stroke. Stroke 2010; 41: 2366-2370
28. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31: 1062-1068
29. Ferro JM. Cardioembolic stroke: an update. Lancet Neurol 2003; 2: 177-188
30. Wang QS, Chen C, Chen XY, et al. Low-molecularweight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-Tris) study. Stroke 2012; 43: 346-349
31. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab 2007; 27: 435-451
32. Qureshi AI, Suri MF, Zhou J, Divani AA. African American women have poor long-Term survival following ischemic stroke. Neurology 2006; 67: 1623-1629
33. McHughen SA, Rodriguez PF, Kleim JA, et al. BDNF val66met polymorphism influences motor system function in the human brain. Cereb Cortex 2010; 20: 1254-1262
34. Henderson KM, Clark CJ, Lewis TT, et al. Psychosocial distress and stroke risk in older adults. Stroke 2013; 44: 367-372
35. Chen R, McKevitt C, Crichton SL, Rudd AG, Wolfe CD. Socioeconomic deprivation and provision of acute and long-Term care after stroke: the South London Stroke Register cohort study. J Neurol Neurosurg Psychiatry 2014; 85: 1294-1300
36. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007; 357: 562-571
37. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005; 36: 880-890
38. Adams HP Jr, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008; 39: 87-99
39. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55
40. Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: an example and lesson. Med Care 2007; 45: S143-S148
41. Pearl J. Remarks on the method of propensity score. Stat Med 2009; 28: 1415-1416
42. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston, MA: Houghton Mifflin; 2002: 164
43. Basu A, Polsky D, Manning WG. Use of propensity scores in non-linear response models: the case for health care expenditures. Available at: http://www.nber.org/papers/w14086.pdf. Accessed January 9, 2015
44. Bergstralh EJ, Kosanke JL.computerized Matching of Controls. Technical Report Series No. 56. Available at: http://www.mayo.edu/research/documents/biostat-56pdf/doc-10026923. Accessed December 19, 2014
45. Kunte H, Busch MA, Trostdorf K, et al. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol 2012; 72: 799-806
46. Mandava P, Krumpelman CS, Murthy SB, Kent TA A critical review of stroke trial analytical methodology: outcome measures, study design, and correction for imbalances. In: Lapchak PA, Zhang JH, eds. Translational Stroke Research: From Target Selection to Clinical Trials, Ch. New York: Springer; 2012: 833-861
47. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007; 38: 3055-3062
48. Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 2012; 379: 2352-2363
49. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607
50. Quinn TJ, Dawson J, Walters MR, Lees KR. Exploring the reliability of the modified Rankin Scale. Stroke 2009; 40: 762-766
51. Wilson JT, Slieker FJ, Legrand V, Murray G, Stocchetti N, Maas AI. Observer variation in the assessment of outcome in traumatic brain injury: experience from a multicenter, international randomized clinical trial. Neurosurgery 2007; 61: 123-128
52. Mandava P, Krumpelman CS, Shah JN, White DL, Kent TA. Quantification of errors in ordinal outcome scales using shannon entropy: effect on sample size calculations. PLoS One 2013; 8: e67754
53. Whitehead J. Sample size calculations for ordered categorical data. Stat Med 1993; 12: 2257-2271
54. McPherson GC, Campbell MK, Elbourne DR. Investigating the relationship between predictability and imbalance in minimisation: a simulation study. Trials 2013; 14: 86
55. Zhao W, Hill MD, Palesch Y. Minimal sufficient balance: a new strategy to balance baseline covariates and preserve randomness of treatment allocation. Stat Methods Med Res Epub 2012 Jan 26
56. Berkhemer OA, Fransen PS, Beumer D, et al A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015; 372: 11-20
57. Conolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patient with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
58. Boutron I, Ravaud P, Nizard R. The design and assessment of prospective randomised, controlled trials in orthopaedic surgery. Bone Joint J 2007; 89-B: 858-863
59. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012; 5: 480-486
60. Lyden PD. In anticipation of International Stroke Trial-3 (IST-3). Stroke 2012; 43: 1691-1694